The decision also makes BMS' Opdivo (nivolumab) the first PD-1 checkpoint inhibitor to be approved via an accelerated assessment in Europe, signalling the European Commission's attempts to keep up ...

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma. Among patients with ...

The trial compared the combination therapy against the company’s current standard of care (SoC) melanoma treatment nivolumab (Opdivo ... gene 3 (LAG-3), a molecule typically found on the ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab ...

IPI-549 is already in a phase 1/1b study in advanced solid tumours as a monotherapy and in combination with Opdivo. Infinity says its molecule is the only selective PI3K-gamma inhibitor in ...

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo. Among patients with muscle-invasive bladder cancer (MIBC), treatment with ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on ...